• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

Aastrom


  • Please log in to reply
150 replies to this topic

#31 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 February 2011 - 02:15 PM

DIARY - Non-S&P 500 Earnings for Monday, February 28, 2011
Reuters - 5 hours ago
ESTIMATE EST EPS 28 Feb BMO Q4 Almost Family (AFAM.O) 0.78 7 0.74 28 Feb AMC Q4 ALTRA HOLDINGS INC (AIMC.O) 0.22 6 0.14 28 Feb AMC Q4 AMYRIS INC (AMRS.O) -0.49 5 N/A 28 Feb BMO Q4 ALLIED NEVADA ...

View the full article

#32 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 February 2011 - 09:13 PM

Aastrom Biosciences Reports Operating Results For The Quarter And Six Months Ended December 31, 2010
TheStreet.com - 1 hour ago
By GlobeNewswire 02/28/11 - 04:00 PM EST ANN ARBOR, Mich., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the ...

View the full article

#33 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 01 March 2011 - 09:10 PM

Cytori: A Low Risk Stem Cell Play
Minyanville.com - 2 hours ago
By James Anderson Mar 01, 2011 4:00 pm The biotech company has had successful clinical trials yet is unloved by the market. Here's why investors should start a position now. Typically, early-stage ...

View the full article

sponsored ad

  • Advert

#34 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 02 March 2011 - 03:53 PM

Aastrom Biosciences Inc (ASTM) Given “Outperform” Rating by Zacks Investment Research Analysts
American Banking News - 1 hour ago
Equities research analysts at Zacks Investment Research reiterated an “outperform” rating on shares of Aastrom Biosciences Inc (NASDAQ: ASTM) in a research note to investors on Tuesday. The ...

View the full article

#35 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 04 March 2011 - 04:30 PM

Regulatory Approval an Ongoing Challenge for Drug Makers
Marketwire - 1 hour ago
NEW YORK, NY--(Marketwire - March 4, 2011) - There is plenty of optimism surrounding the healthcare sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile ...

View the full article

#36 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 10 March 2011 - 05:55 AM

Aastrom to Present at the Cowen 31st Annual Healthcare Conference
IEWY News - 1 hour ago
ANN ARBOR, Mich., — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today ...

View the full article

#37 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 March 2011 - 07:07 PM

Placenta vs bone marrow in battle to save limbs
Reuters - 2 hours ago
By Anand Basu and Shravya Jain BANGALORE (Reuters) - Two stem cell research firms are going head-to-head in the race to develop a first treatment for critical limb ischemia (CLI), where severely ...

View the full article

#38 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 21 March 2011 - 05:38 PM

Aastrom Announces Outcome of Special Meeting of Shareholders
GlobeNewsWire - 2 hours ago
ANN ARBOR, Mich., March 21, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic ...

View the full article

#39 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 March 2011 - 04:24 AM

Aastrom Announces Date of 2011 Annual Meeting of Shareholders
IEWY News - 1 hour ago
ANN ARBOR, Mich., — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded, patient specific cellular therapies for the treatment of severe, chronic cardiovascular diseases ...

View the full article

#40 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 March 2011 - 03:04 PM

Analysts' New Coverage for March, 28th (ARMH, ASTM, ATML, IACI, LEAP, PCS, RGNC)
American Banking News - 1 hour ago
Cowen analysts initiated coverage on shares of ARM Holdings plc (NASDAQ: ARMH). They set a “neutral” rating on the stock. Stifel Nicolaus analysts initiated coverage on shares of Aastrom ...

View the full article

#41 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 March 2011 - 12:43 PM

Drug stocks sluggish, but Aastrom soars
MarketWatch - 3 hours ago
By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) — Drug stocks traded in the doldrums Monday, lagging modest early gains for the broader equities market, but Aastrom Biosciences managed ...
Aastrom Biosciences, Inc. (ASTM) Rated at “Buy” by Stifel Nicolaus - FavStocks

View the full article

#42 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 March 2011 - 07:00 PM

Stocks Gapping Up for March, 28th (ACHN, ALU, ARII, ASTM, BCDS, BLDP, BSET)
American Banking News - 46 minutes ago
Shares of Achillion Pharmaceuticals Inc (ACHN) are trading up 3% today. The stock previously closed at $6.78 and last traded at $7.00. Shares of Alcatel Lucent ADR Reptg 1 Ord Shs (ALU) are ...

View the full article

#43 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 01 April 2011 - 01:10 PM

Aastrom to Present at the 10th Annual Needham & Company Healthcare Conference
GlobeNewsWire - 1 hour ago
ANN ARBOR, Mich., April 1, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded patient-specific cellular therapies for the treatment of severe ...

View the full article

#44 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 04 April 2011 - 01:18 PM

Aastrom (ASTM) Transfers Cell Cassette Manufacturing; Ixmyelocel-T Name Accepted by US FDA
StreetInsider.com - 3 hours ago
Aastrom Biosciences, Inc. (Nasdaq: ASTM) has transferred cell cassette manufacturing to ATEK Medical under the strategic partnership announced in October 2010. In addition, Aastrom announced today ...

View the full article

#45 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 04 April 2011 - 01:10 PM

Aastrom Announces Key Manufacturing Milestone and New Generic Name for Its Cell Therapy Product
GlobeNewsWire - 3 hours ago
ANN ARBOR, Mich., April 4, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded, patient-specific cellular therapies for the treatment of severe ...
Aastrom Jumps On Rating, Manufacturing Milestone - FOX Business

View the full article

#46 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 05 April 2011 - 11:55 AM

Aastrom transfers cell cassette manufacturing to ATEK Medical
Pharmaceutical Business Review - 4 hours ago
Aastrom Biosciences has completed an important product manufacturing milestone with the transfer of cell cassette manufacturing to ATEK Medical under the strategic partnership announced in October ...
Aastrom Biosciences, Inc. (ASTM) Completes Manufacturing Milestone - FavStocks
Biotech Stock Watch; Aastrom Biosciences on Track with Recent Milestone - Beacon Equity Research

View the full article

#47 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 06 April 2011 - 01:10 AM

BioTime and XenneX Form LifeMap Sciences, Inc. to Create Roadmap for Regenerative Medicine
4-traders - 2 hours ago
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has formed LifeMap Sciences, Inc ...

View the full article

#48 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 08 April 2011 - 02:21 PM

LifeMap born to create stem cell database
FierceBiotech IT - 58 minutes ago
FierceBiotech IT updates senior biotech, pharma, and IT leaders on how IT advances are shaping clinical trials and clinical research. Get your weekly briefing on clinical trial design and ...

View the full article

#49 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 18 April 2011 - 04:41 PM

Competition Between Aastrom Bio and Pluristem Heating Up
Seeking Alpha - 3 hours ago
Peripheral Arterial Disease (PAD) affects an estimated 10% to 20% of all people over the age of 55, with prevalence increasing with age. Prevalence of PAD is also significantly higher, about 30 ...

View the full article

#50 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 02 May 2011 - 03:34 PM

Stem-Cell Researchers Gain On US Court Decision
Wall Street Journal - 8 hours ago
Shares of several stem-cell-research groups were on a roll early Monday in the wake of a US appeals court decision Friday that will allow researchers who experiment with human embryonic stem cells ...
Select Stem Cell Stocks Surge After Favorable Court Ruling (PSTI, STEM, ATHX, ASTM, GERN, CUR, NBS, OSIR) - tickerspy Newswire

View the full article

#51 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 06 May 2011 - 08:33 PM

Aastrom CEO Tim Mayleben to Present at the World Stem Cells and Regenerative Medicine Congress 2011 in London
GlobeNewsWire - 1 hour ago
ANN ARBOR, Mich., May 6, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded patient-specific cellular therapies for the treatment of severe, chronic ...

View the full article

#52 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 14 May 2011 - 11:22 AM

Ichimoku Cloud Turned Green – ACOR, ADBE, AFSI, AMZN, ASTM
Zacquisha - 44 minutes ago
By Matt Tindall at 14 May, at 04 : 46 AM Acorda Therapeutics Inc. (NASDAQ:ACOR) went up 3.09%, to close at $26.05 and its overall traded volume was 622,055.00 shares in the last trading session ...

View the full article

#53 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 16 May 2011 - 07:49 PM

Investor Stem Cell prepares for Investor deluge: Increases Coverage of Stem Cell Companies:
PR-USA.net - 17 minutes ago
Investor Stem Cell announced today that it would increase coverage of the following companies in the regenerative medicine sector: Advanced Cell Technology (OTC:ACTC), Geron Corporation (NASDAQ ...

View the full article

#54 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 16 May 2011 - 08:05 PM

Aastrom Biosciences Reports First Quarter 2011 Financial Results and Corporate Developments
GlobeNewsWire - 3 hours ago
ANN ARBOR, Mich., May 16, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific, expanded multi-cellular therapies for the treatment of severe ...
TRADING HIGHER ON HEAVY VOLUME ARE SHARES OF AASTROM BIOSCIENCES ON 1.1X ABOVE-AVERAGE VOLUME (ASTM) - Zacks.com
Aastrom Biosciences Inc. Reports Operating Results (10-Q) - GuruFocus.com

View the full article

#55 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 16 May 2011 - 07:49 PM

Investor Stem Cell prepares for Investor deluge: Increases Coverage of Stem Cell Companies:
PR-USA.net - 3 hours ago
Investor Stem Cell announced today that it would increase coverage of the following companies in the regenerative medicine sector: Advanced Cell Technology (OTC:ACTC), Geron Corporation (NASDAQ ...

View the full article

#56 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 17 May 2011 - 07:55 AM

Aastrom Biosciences Q1 net loss up
istockAnalyst.com - 2 hours ago
(Source: Datamonitor) Aastrom Biosciences, Inc., a developer of patient-specific, expanded multi-cellular therapies for the treatment of severe, chronic cardiovascular diseases, has reported a net ...

View the full article

#57 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 17 May 2011 - 01:01 PM

Aastrom to Present Results From Two Studies of Autologous Bone Marrow-Derived ixmyelocel-T at the International Society for Cellular Therapy Meeting
GlobeNewsWire - 4 hours ago
ANN ARBOR, Mich., May 17, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific, expanded multi-cellular therapies for the treatment of severe ...

View the full article

#58 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 18 May 2011 - 07:52 AM

Parabolic SAR Buy Signals - ABFS, ASTM, BGNN, BODY, CHUX
acovi - 2 hours ago
Arkansas Best Corporation (NASDAQ:ABFS) slid -1.32%, to close at $23.87 and its overall traded volume was 299,112.00 shares in the last trading session. ABFS shares were trading within the range ...

View the full article

#59 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 17 May 2011 - 11:41 AM

Needham & Company Reiterates a 'Buy' on Aastrom Biosciences (ASTM); 1Q11/Early 2Q11 Review: Are We There Yet?
StreetInsider.com - May 17, 2011
Needham analyst says, "Last night, Aastrom reviewed its 1Q11 results and provided its 2011 outlook. The Company is currently evaluating ixmyelocel-T, an autologous mixed-cell ... StreetInsider.com ...

View the full article

#60 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 25 May 2011 - 09:02 PM

Aastrom Announces Collaboration With CPC Clinical Research for the Phase 3 REVIVE Study in Critical Limb Ischemia
GlobeNewsWire - 39 minutes ago
ANN ARBOR, Mich., May 25, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe ...

View the full article




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users